Skip to main content
. 2018 Mar;188(3):586–599. doi: 10.1016/j.ajpath.2017.10.023

Figure 6.

Figure 6

Antisense (as)-miR-31-3p exacerbates dextran sodium sulfate (DSS)-induced colitis. A: Timeline of as-miR-31-3p treatment in 2% DSS-induced colitis. B: Percentage of initial body weight of each group of mice during treatment. C: Histologic changes in colons of controls or as-miR-31-3p–treated C57BL6/J mice in DSS colitis model. D: Expression level of miR-31-3p after intracolonic administration of as-miR-31-3p. E: Colon length of each group of mice. F: Disease activity index scores of as-miR-31-3p–treated mice with DSS-induced colitis. ∗G: Histopathology score of as-miR-31-3p–treated mice with DSS-induced colitis. H: Crypt damage score of as-miR-31-3p–treated mice with DSS-induced colitis. I: Edema score of as-miR-31-3p–treated mice with DSS-induced colitis. J: Expression of tumor necrosis factor (TNF)-α, CXCL10, and chemokine (C-C motif) ligand 2 (CCL2) in the colon tissue of as-miR-31-3p– or anti-miR-control–treated DSS-induced colitis models. Data are expressed as means ± SD. n = 8. ∗P < 0.05. Scale bar = 100 μm.